Publications

Publication 2023

MM and MGUS

  1. Dimopoulos MA, Moreau P, Augustson B, Castro N, Pika T, Delimpasi S, De la Rubia J, Maiolino A, Reiman T, Martinez-Lopez J, Martin T, Mikhael J, Yong K, Risse ML, Asset G, Marion S, Hajek R. Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis. Am J Hematol. 2023 Jan;98(1):E15-E19. doi: 10.1002/ajh.26602. Epub 2022 Jun 4.PMID: 35604280 IF 13,268
  2. Haertle L, Barrio S, Munawar U, Han S, Zhou X, Simicek M, Vogt C, Truger M, Fernandez RA, Steinhardt M, Weingart J, Snaurova R, Nerreter S, Teufel E, Garitano-Trojaola A, Da Viá M, Ruiz-Heredia Y, Rosenwald A, Bolli N, Hajek R, Raab P, Raab MS, Weinhold N, Haferlach C, Haaf T, Martinez-Lopez J, Einsele H, Rasche L, Kortüm KM. Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma. Clin Cancer Res. 2023 Jan 4;29(1):279-288. doi: 10.1158/1078-0432.CCR-22-1161. IF 13,801
  3. Palladini G, Schönland S, Merlini G, Milani P, Jaccard A, Bridoux F, Dimopoulos MA, Ravichandran S, Hegenbart U, Roeloffzen W, Cibeira MT, Agis H, Minnema MC, Bergantim R, Hájek R, João C, Leonidakis A, Cheliotis G, Sonneveld P, Kastritis E, Wechalekar A. The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018. Blood Cancer J. 2023 Jan 25;13(1):19. doi: 10.1038/s41408-023-00789-8. IF 9,812
  4. Maisnar V, Pour L, Spicka I, Jelinek T, Minarik J, Jungova A, Stork M, Straub J, Radocha J, Pika T, Pospisilova L, Nair S, Kunovszki P, Hajek R. Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech Registry Data. Clin Lymphoma Myeloma Leuk. 2023 Feb;23(2):145-153. doi: 10.1016/j.clml.2022.11.001. Epub 2022 Nov 6. IF 2,822

Publication 2022

MM and MGUS

  1. Adam Z, Řehák Z, Adamová Z, Pour L, Dvořáková K, Packová B, Koukalová R, Krejčí M, Krejčí M, Štork M, Sandecká V, Boichuk I, Král Z. Slow increase of bilirubin concentration during administration of lenalidomide, bortezomib and dexamethasone for multiple myeloma (unmasking previously undiagnosed Gilbert syndrome) and disappearance of necrobiotic xanthogranuloma after complete remission of multiple myeloma. Klin Onkol. 2022 Summer;35(4):315-322. doi: 10.48095/ccko2022315.PMID: 35989089 
  2. Beksac M, Spicka I, Hajek R, Bringhen S, Jelínek T, Martin T, Mikala G, Moreau P, Symeonidis A, Rawlings AM, van de Velde H, Richardson PG. Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMA. Leuk Res. 2022 Nov;122:106948. doi: 10.1016/j.leukres.2022.106948. Epub 2022 Sep 6.PMID: 36108425. IF 3,715
  3. Capra M, Martin T, Moreau P, Baker R, Pour L, Min CK, Leleu X, Mohty M, Segura MR, Turgut M, LeBlanc R, Risse ML, Malinge L, Schwab S, Dimopoulos M. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis. Haematologica. 2022 Jun 1;107(6):1397-1409.  doi: 10.3324/haematol.2021.279229. IF 11,049
  4. Clay-Gilmour A, Chattopadhyay S, Hildebrandt MAT, Thomsen H, Weinhold N, Vodicka P, Vodickova L, Hoffmann P, Nöthen MM, Jöckel KH, Schmidt B, Langer C, Hajek R, Hallmans G, Pettersson-Kymmer U, Ohlsson C, Späth F, Houlston R, Goldschmidt H, Manasanch EE, Norman A, Kumar S, Rajkumar SV, Slager S, Försti A, Vachon CM, Hemminki K. Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6. Blood Cancer J. 2022 Apr 13;12(4):60. doi: 10.1038/s41408-022-00658-w.PMID: 35418122. IF 9,812
  5. Delimpasi S, Mateos MV, Auner HW, Gavriatopoulou M, Dimopoulos MA, Quach H, Pylypenko H, Hájek R, Leleu X, Dolai TK, Sinha DK, Venner CP, Benjamin R, Garg MK, Doronin V, Levy Y, Moreau P, Chai Y, Arazy M, Shah J, Shacham S, Kauffman MG, Richardson PG, Grosicki S. Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study. Am J Hematol. 2022 Mar 1;97(3):E83-E86. doi: 10.1002/ajh.26434. Epub 2021 Dec 29.PMID: 34882831. IF 13,268
  6. Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9.PMID: 35550060. IF 30,153
  7. Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, Hájek R, Schjesvold F, Cavo M, Goldschmidt H, Facon T, Einsele H, Boccadoro M, San-Miguel J, Sonneveld P, Mey U; EHA Guidelines Committee ESMO Guidelines Committee. Electronic address: guidelines@ehaweb.org. Corrigendum to "Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up'": [Ann Oncol Volume 33, Issue 1, January 2022, Page 117]. Ann Oncol. 2022 Sep;33(9):988. doi: 10.1016/j.annonc.2022.05.004. Epub 2022 Jul 6.PMID: 35810138. IF 51,769
  8. Dura M, Pock L, Cetkovska P, Jungova A, Nemejcova K, Stork J. A case of cutaneous collagenous vasculopathy associated with multiple myeloma and with a pathogenic variant of the glucocerebrosidase gene. J Cutan Pathol. 2022 Aug;49(8):717-721. doi: 10.1111/cup.14227. Epub 2022 Mar 23.PMID: 35294059. IF 1,458
  9. Facon T, Moreau P, Martin TG, Spicka I, Oriol A, Koh Y, Lim A, Mikala G, Rosiñol L, Yağci M, Cavo M, Yong K, Risse ML, Asset G, Schwab S, Martinez G. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis. Hematol Oncol. 2022 Dec;40(50):1020-1029. doi: 10.1002/hon.3038. PMID: 35653225. IF 4,85
  10. Gozzetti A, Guarnieri A, Zamagni E, Zakharova E, Coriu D, Bittrich M, Pika T, Tovar N, Schutz N, Ciofini S, Peña C, Rocchi S, Rassner M, Avivi I, Waszczuk-Gajda A, Chhabra S, Usnarska-Zubkiewicz L, González-Calle V, Mateos MV, Bocchia M, Bigi F, Füllgraf H, Bhasin-Chhabra B, Gentile M, Davila J, Vesole DH, Cavo M, Thapa B, Crusoe E, Einsele H, Legiec W, Charliński G, Jurczyszyn A. Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors. Am J Hematol. 2022 Jul;97(7):877-884. doi: 10.1002/ajh.26566. Epub 2022 Apr 20.PMID: 35389534. IF 13,268
  11. Gregorova J, Vychytilova-Faltejskova P, Kramarova T, Knechtova Z, Almasi M, Stork M, Pour L, Kohoutek J, Sevcikova S. Proteomic analysis of the bone marrow microenvironment in extramedullary multiple myeloma patients. Neoplasma. 2022 Mar;69(2):412-424. doi: 10.4149/neo_2021_210527N715. Epub 2022 Jan 18.PMID: 35037760. IF 3,409
  12. Hübnerová P, Karhanová M, Krhovská P, Minařík J, Mlčák P, Pašková B, Schreiberová Z, Šínová I, Zapletalová J, Šín M. Retinal oxygen saturation in monoclonal gammopathies patients: A pilot study. Acta Ophthalmol. 2022 Aug 25. doi: 10.1111/aos.15239. Online ahead of print.PMID: 36004612. IF 3,988
  13. Jelinek T, Sevcikova T, Zihala D, Popkova T, Kapustova V, Broskevicova L, Capkova L, Rihova L, Bezdekova R, Sevcikova S, Zidlik V, Havel M, Plonkova H, Jungova A, Minarik J, Stork M, Pour L, Pavlicek P, Spicka I, Maisnar V, Radocha J, Simicek M, Hajek R. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. Leukemia. 2022 Jan;36(1):288-291. doi: 10.1038/s41375-021-01343-w. Epub 2021 Jul 10.PMID: 34247197 IF 11,528. IF 12,897
  14. Jelinek T, Bezdekova R, Zihala D, Sevcikova T, Anilkumar Sithara A, Pospisilova L, Sevcikova S, Polackova P, Stork M, Knechtova Z, Venglar O, Kapustova V, Popkova T, Muronova L, Chyra Z, Hrdinka M, Simicek M, Garcés JJ, Puig N, Cedena MT, Jurczyszyn A, Castillo JJ, Penka M, Radocha J, Mateos MV, San-Miguel JF, Paiva B, Pour L, Rihova L, Hajek R. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma. J Clin Oncol. 2022 Oct 31:JCO2201226. doi: 10.1200/JCO.22.01226. Online ahead of print. PMID: 36315921 IF 50, 739
  15. Krejci M, Adam Z, Krejci M, Pour L, Sandecka V, Stork M. CAR-T cells for the treatment of relapsed/refractory multiple myeloma in 2022: efficacy and toxicity. Neoplasma. 2022 Sep;69(5):1008-1018. doi: 10.4149/neo_2022_220504N477. Epub 2022 Jul 29.PMID: 35900317. IF 3,409
  16. Krhovska P, Pika T, Proskova J, Balcarkova J, Zapletalova J, Bacovsky J, Minarik J. Bone metabolism parameters and their relation to cytogenetics in multiple myeloma. Eur J Haematol. 2022 Jul;109(1):75-82. doi: 10.1111/ejh.13771. Epub 2022 Mar 24.PMID: 35306691. IF 3,674
  17. Landgren O, Weisel K, Rosinol L, Touzeau C, Turgut M, Hajek R, Mollee P, Kim JS, Shu N, Hu X, Li C, Usmani SZ. Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study. Br J Haematol. 2022 Sep;198(6):988-993. doi: 10.1111/bjh.18233. Epub 2022 May 24.PMID: 35608261. IF 8,615
  18. Leleu X, Martin T, Weisel K, Schjesvold F, Iida S, Malavasi F, Manier S, Chang-Ki Min, Ocio EM, Pawlyn C, Perrot A, Quach H, Richter J, Spicka I, Yong K, Richardson PG. Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes. Ann Hematol. 2022 Oct;101(10):2123-2137. doi: 10.1007/s00277-022-04917-5. Epub 2022 Aug 9.PMID: 35943588. IF 4,03
  19. Luzna P, Weiser Drozdkova D, Flodrova P, Ondruskova K, Uberall I, Minarik J, Kolar Z, Smesny Trtkova K. Global DNA methylation and increased DNMT3A expression in multiple myeloma patients. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022 Feb 16. doi: 10.5507/bp.2022.006. Online ahead of print.PMID: 35173353. IF 1,648
  20. Martin T, Mikhael J, Hajek R, Kim K, Suzuki K, Hulin C, Garg M, Quach H, Sia H, George A, Konstantinova T, Risse ML, Asset G, Macé S, van de Velde H, Moreau P. Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma. Blood Adv. 2022 Aug 9;6(15):4506-4515. doi: 10.1182/bloodadvances.2021006713.PMID: 35594559. IF 7,642
  21. Martin T, Richardson PG, Facon T, Moreau P, Perrot A, Spicka I, Bisht K, Inchauspé M, Casca F, Macé S, Van de Velde H, Suzuki K. Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA. Haematologica. 2022 Oct 1;107(10):2485-2491. doi: 10.3324/haematol.2022.280660.PMID: 35734925. IF 11,049 
  22. Mateos MV, Rigaudeau S, Basu S, Spicka I, Schots R, Wrobel T, Cook G, Beksac M, Gries KS, Kudva A, Tromp B, Van Rampelbergh R, Pei H, Wroblewski S, Carson R, Delioukina M, White D.  Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma. J Oncol Pharm Pract. 2022 Sep 6:10781552221103551. doi: 10.1177/10781552221103551. Online ahead of print.PMID: 36067063. IF 1,416
  23. Paiva B, Manrique I, Dimopoulos MA, Gay F, Min CK, Zweegman S, Spicka I, Teipel R, Mateos MV, Giuliani N, Cavo M, Rojas C, Fu W, Suryanarayan K, Vorog A, Li C, Wang B, Estevam J, Labotka R, Dash AB. MRD dynamics during maintenance for improved prognostication of 1280 myeloma patients in TOURMALINE-MM3 and -MM4 trials. Blood. 2022 Sep 21:blood.2022016782. doi: 10.1182/blood.2022016782. Online ahead of print.PMID: 36130300. IF 25,669
  24. Richardson PG, Perrot A, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Malinge L, Dubin F, van de Velde H, Anderson KC. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncol. 2022 Mar;23(3):416-427. doi: 10.1016/S1470-2045(22)00019-5. Epub 2022 Feb 10.PMID: 35151415. IF 54,433
  25. Schjesvold FH, Dimopoulos MA, Delimpasi S, Robak P, Coriu D, Legiec W, Pour L, Špička I, Masszi T, Doronin V, Minarik J, Salogub G, Alekseeva Y, Lazzaro A, Maisnar V, Mikala G, Rosiñol L, Liberati AM, Symeonidis A, Moody V, Thuresson M, Byrne C, Harmenberg J, Bakker NA, Hájek R, Mateos MV, Richardson PG, Sonneveld P; OCEAN (OP-103) Investigators. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. Lancet Haematol. 2022 Feb;9(2):e98-e110. doi: 10.1016/S2352-3026(21)00381-1. Epub 2022 Jan 12.PMID: 35032434. IF 30,153
  26. Sonneveld P, Zweegman S, Cavo M, Nasserinejad K, Broijl A, Troia R, Pour L, Croockewit S, Corradini P, Patriarca F, Wu K, Droogendijk J, Bos G, Hajek R, Teresa Petrucci M, Ypma P, Zojer N, Minnema MC, Boccadoro M. Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma. Hemasphere. 2022 Sep 30;6(10):e786. doi: 10.1097/HS9.0000000000000786. eCollection 2022 Oct.PMID: 36204691. IF 8,3 
  27. Spicka I, Moreau P, Martin TG, Facon T, Martinez G, Oriol A, Koh Y, Lim A, Mikala G, Rosiñol L, Yağci M, Cavo M, Risse ML, Asset G, Macé S, van de Velde H, Yong K. Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis. Eur J Haematol. 2022 Nov;109(5):504-512. doi: 10.1111/ejh.13835. Epub 2022 Aug 18.PMID: 35871357. IF 3,674
  28. Stork M, Sevcikova S, Minarik J, Krhovska P, Radocha J, Pospisilova L, Brozova L, Jarkovsky J, Spicka I, Straub J, Pavlicek P, Jungova A, Jelinek T, Sandecka V, Maisnar V, Hajek R, Pour L. Identification of patients at high risk of secondary extramedullary multiple myeloma development. Br J Haematol. 2022 Feb;196(4):954-962.  doi: 10.1111/bjh.17925. Epub 2021 Nov 2. IF 8,615
  29. Stork M, Sevcikova S, Jelinek T, Minarik J, Radocha J, Pika T, Pospisilova L, Spicka I, Straub J, Pavlicek P, Jungova A, Knechtova Z, Sandecka V, Maisnar V, Hajek R, Pour L. Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas. Biomedicines. 2022 Oct 11;10(10):2535. doi: 10.3390/biomedicines10102535.PMID: 36289797 IF 4,757
  30. Termini R, Zihala D, Terpos E, Pérez-Montaña A, Jelinek T, Raab M, Weinhold N, Mai EK, Grab AL, Corre J, Vergez F, Sacco A, Chiarini M, Giustini V, Tucci A, Rodríguez S, Moreno C, Perez C, Maia C, Martin-Sanchez E, Guerrero C, Botta C, Garcés JJ, Lopez A, Tamariz-Amador LE, Prósper F, Bargay J, Cabezudo ME, Ocio EM, Hájek R, Martinez-Lopez J, Solano F, Iglesias R, Paiva A, Geraldes C, Matos Silva H, Gomez C, De Arriba F, Ludwig H, Garcia-Guiñon A, Casanova M, Alegre A, Cabañas V, Sirvent M, Oriol A, De la Rubia J, Hernández-Rivas JÁ, Palomera L, Sarasa M, Rios P, Puig N, Mateos MV, Flores-Montero J, Orfao A, Goldschmidt H, Avet-Loiseau H, Roccaro AM, San-Miguel JF, Paiva B. Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma. Clin Cancer Res. 2022 Nov 1;28(21);4771-4781. doi: 10.1158/1078-0432.CCR-22-1594. PMID: 36074126. IF 13,801
  31. Trtkova KS, Luzna P, Drozdkova DW, Cizkova K, Janovska L, Gursky J, Prukova D, Frydrych I, Hajduch M, Minarik J. The epigenetic impact of suberohydroxamic acid and 5‑Aza‑2'‑deoxycytidine on DNMT3B expression in myeloma cell lines differing in IL‑6 expression. Mol Med Rep. 2022 Oct;26(4):321. doi: 10.3892/mmr.2022.12837. Epub 2022 Aug 31.PMID: 36043519. IF 3,423
  32. Usmani SZ, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis NJ, Flogegard M, Bladé J, Moreau P, Kaiser M, Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Lantz K, O'Rourke L, Heuck C, Delioukina M, Qin X, Nnane I, Qi M, Mateos MV. Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma. Haematologica. 2022 Oct 1;107(10):2408-2417. doi: 10.3324/haematol.2021.279459.PMID: 35354247. IF 11,046 
  33. Vdovin A, Jelinek T, Zihala D, Sevcikova T, Durech M, Sahinbegovic H, Snaurova R, Radhakrishnan D, Turi M, Chyra Z, Popkova T, Venglar O, Hrdinka M, Hajek R, Simicek M. The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma. Nat Commun. 2022 Nov 10;13(1):6820. doi: 10.1038/s41467-022-34654-2.PMID: 36357400 IF 17,694
  34. Venglar O, Bago JR, Motais B, Hajek R, Jelinek T. Natural Killer Cells in the Malignant Niche of Multiple Myeloma. Front Immunol. 2022 Jan 11;12:816499. doi: 10.3389/fimmu.2021.816499. eCollection 2021.PMID: 35087536. IF 8,787
  35. Vlachová M, Gregorová J, Vychytilová-Faltejsková P, Gabło NA, Radová L, Pospíšilová L, Almáši M, Štork M, Knechtová Z, Minařík J, Popková T, Jelínek T, Hájek R, Pour L, Říhová L, Ševčíková S. Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma. Int J Mol Sci. 2022 Nov 25;23(23):14765. doi: 10.3390/ijms232314765. IF 6,208
  36. Zátopková M, Ševčíková T, Fanfani V, Chyra Z, Rihova L, Bezdekova R, Žihala D, Growková K, Filipova J, Černá L, Broskevičová L, Kryukov F, Minařík J, Smejkalová J, Maisnar V, Harvanová L, Pour L, Jungova A, Popková T, Bago JR, Anilkumar Sithara A, Hrdinka M, Jelinek T, Šimíček M, Stracquadanio G, Hajek R. Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine. Blood Adv. 2022 Jan 25;6(2):368-372.  doi: 10.1182/bloodadvances.2020003876. IF 7,642

Other projects 2022

  1. Adam Z, Adamová Z, Pour L, Řehák Z, Koukalová R, Král Z. Rosai-Dorfman-Destombes disease - histiocytic disorder with inflammatory manifestation. Klin Onkol. 2022 Summer;35(4):262-170. doi: 10.48095/ccko2022262.PMID: 35989082 
  2. Adam Z, Zeman D, Čermák A, Dastych M, Doubková M, Horváth T, Skorkovská Š, Adamová Z, Řehák Z, Koukalová R, Pour L, Štork M, Krejčí M, Sandecká V, Ševčíková S, Král Z. IgG4-related disease. Clinical manifestation differential diagnosis and recent International Diagnostic Criteria for IgG4-related disease. Vnitr Lek. 2022 Fall;68(E-5):4-19. doi: 10.36290/vnl.2022.070.PMID: 36283812 
  3. Adam Z, Pour L, Tomíška M, Starý K, Horváth T, Doubková M, Nebeský T, Řehák Z, Koukalová R, Krejčí M, Krejčí M, Boichuk I, Štork M, Ševčíková S, Adamová Z, Král Z. Langerhans cell histiocytosis (LCH). Overview of symptoms of LCH, which may lead the patients to any of these medical specialists. Vnitr Lek. 2022 Summer;68(E-2):11-21.PMID: 36208940
  4. Adam Z, Řehák Z, Adamová Z, Koukalová R, Pour L, Krejčí M, Boichuk I, Sandecká V, Krejčí M, Štork M, Ševčíková S, Král Z. Multicentric Castlemans disease. Symptoms, diagnostics and therapy. Vnitr Lek. 2022 Winter;68(1):41-53.PMID: 35459346 
  5. Botta C, Maia C, Garcés JJ, Termini R, Perez C, Manrique I, Burgos L, Zabaleta A, Alignani D, Sarvide S, Merino J, Puig N, Cedena MT, Rossi M, Tassone P, Gentile M, Correale P, Borrello I, Terpos E, Jelinek T, Paiva A, Roccaro A, Goldschmidt H, Avet-Loiseau H, Rosinol L, Mateos MV, Martinez-Lopez J, Lahuerta JJ, Bladé J, San-Miguel JF, Paiva B. FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology. Blood Adv. 2022 Jan 25;6(2):690-703. doi: 10.1182/bloodadvances.2021005198.PMID: 34587246. IF 7,642
  6. Buske C, Dreyling M, Alvarez-Larrán A, Apperley J, Arcaini L, Besson C, Bullinger L, Corradini P, Giovanni Della Porta M, Dimopoulos M, D'Sa S, Eich HT, Foà R, Ghia P, da Silva MG, Gribben J, Hajek R, Harrison C, Heuser M, Kiesewetter B, Kiladjian JJ, Kröger N, Moreau P, Passweg JR, Peyvandi F, Rea D, Ribera JM, Robak T, San-Miguel JF, Santini V, Sanz G, Sonneveld P, von Lilienfeld-Toal M, Wendtner C, Pentheroudakis G, Passamonti F. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. ESMO Open. 2022 Apr;7(2):100403. doi: 10.1016/j.esmoop.2022.100403. Epub 2022 Jan 28.PMID: 35272130. IF 6,883
  7. Čerňan M, Szotkowski T, Minařík J, Kolář M, Sauer P, Látal V, Zapletalová J, Papajík T. Breakthrough COVID-19 in Vaccinated Patients with Haematologic Malignancies-The First Single-Centre Experience from the Czech Republic. Life (Basel). 2022 Aug 3;12(8):1184. doi: 10.3390/life12081184.PMID: 36013363. IF 3,253
  8. Demel I, Koristek Z, Motais B, Hajek R, Jelinek T. Natural killer cells: Innate immune system as a part of adaptive immunotherapy in hematological malignancies. Am J Hematol. 2022 Jun 1;97(6):802-817. doi: 10.1002/ajh.26529. Epub 2022 Mar 26.PMID: 35285978. IF 13,268 
  9. Hradská K, Popková T, Skořupová M, Mihályová J, Jelínek T, Lančová J, Schellong N, Hájek R. Management of Treatment-Related Infectious Complications in High-Risk Hemato-Oncological Patients via Telemedicine. Cancer Manag Res. 2022 May 4;14:1655-1661. doi: 10.2147/CMAR.S348923. eCollection 2022.PMID: 35547597. IF 3,602
  10. Mihályová J, Hradská K, Jelínek T, Motais B, Celichowski P, Hájek R. Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders. Int J Mol Sci. 2021 Oct 25;22(21):11470. doi: 10.3390/ijms222111470.PMID: 34768899. IF 6,208
  11. Šušol O, Hájková B, Zelená H, Hájek R. Third dose of COVID-19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres. Br J Haematol. 2022 May;197(3):302-305. doi: 10.1111/bjh.18073. Epub 2022 Feb 28.PMID: 35076937. IF 8,615
  12. Tarasco E, von Krogh AS, Hrdlickova R, Braschler TR, Iwaniec T, Knöbl PN, Hamada E, Pikovsky O, Farese S, Gutwein O, Kessler P, Schultz NH, von Auer C, Windyga J, Friedman K, Hrachovinova I, George JN, Matsumoto M, Schneppenheim R, Lämmle B, Kremer Hovinga JA. Hereditary thrombotic thrombocytopenic purpura and COVID-19: Impacts of vaccination and infection in this rare disease. Res Pract Thromb Haemost. 2022 Oct 21;6(7):e12814. doi: 10.1002/rth2.12814. eCollection 2022 Oct.PMID: 36284639. IF 5,953 
  13. Weinbergerová B, Demel I, Víšek B, Válka J, Čerňan M, Jindra P, Novák J, Stejskal L, Kovácsová F, Kabut T, Szotkowski T, Hájek R, Žák P, Cetkovský P, Král Z, Mayer J. Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience. Hematol Oncol. 2022 Apr;40(2):280-286. doi: 10.1002/hon.2974. Epub 2022 Feb 17.PMID: 35120267. IF 4,85

 

Older publications (2019–2021)

Older publications (2016–2018)

Older publications (2012–2015)

Older publications (2006–2011)

Older publications (1995–2005)